IMAGENEBIO INC (IMA) Stock Fundamental Analysis

NASDAQ:IMA • US45175G2075

6.72 USD
-0.11 (-1.61%)
Last: Feb 27, 2026, 08:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

IMA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. IMA has a great financial health rating, but its profitability evaluates not so good. IMA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year IMA has reported negative net income.
  • In the past year IMA has reported a negative cash flow from operations.
  • In the past 5 years IMA always reported negative net income.
  • IMA had a negative operating cash flow in each of the past 5 years.
IMA Yearly Net Income VS EBIT VS OCF VS FCFIMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of IMA (-30.60%) is comparable to the rest of the industry.
  • With a decent Return On Equity value of -35.21%, IMA is doing good in the industry, outperforming 61.14% of the companies in the same industry.
Industry RankSector Rank
ROA -30.6%
ROE -35.21%
ROIC N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
IMA Yearly ROA, ROE, ROICIMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • IMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMA Yearly Profit, Operating, Gross MarginsIMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • IMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IMA has about the same amount of shares outstanding.
  • The number of shares outstanding for IMA has been reduced compared to 5 years ago.
  • There is no outstanding debt for IMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMA Yearly Shares OutstandingIMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IMA Yearly Total Debt VS Total AssetsIMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of 0.10, we must say that IMA is in the distress zone and has some risk of bankruptcy.
  • IMA has a Altman-Z score (0.10) which is in line with its industry peers.
  • IMA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.1
ROIC/WACCN/A
WACC9.17%
IMA Yearly LT Debt VS Equity VS FCFIMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • IMA has a Current Ratio of 13.24. This indicates that IMA is financially healthy and has no problem in meeting its short term obligations.
  • IMA's Current ratio of 13.24 is amongst the best of the industry. IMA outperforms 82.90% of its industry peers.
  • A Quick Ratio of 13.24 indicates that IMA has no problem at all paying its short term obligations.
  • IMA has a Quick ratio of 13.24. This is amongst the best in the industry. IMA outperforms 82.90% of its industry peers.
Industry RankSector Rank
Current Ratio 13.24
Quick Ratio 13.24
IMA Yearly Current Assets VS Current LiabilitesIMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • IMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.87%, which is quite impressive.
  • Looking at the last year, IMA shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)47.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.48%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, IMA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.28% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y53.37%
EPS Next 2Y31.66%
EPS Next 3Y20.77%
EPS Next 5Y11.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMA Yearly Revenue VS EstimatesIMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2025 2030 2031 2032 2033 100M 200M 300M
IMA Yearly EPS VS EstimatesIMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IMA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMA Price Earnings VS Forward Price EarningsIMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMA Per share dataIMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • IMA's earnings are expected to grow with 20.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.66%
EPS Next 3Y20.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMAGENEBIO INC

NASDAQ:IMA (2/27/2026, 8:11:03 PM)

6.72

-0.11 (-1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-04
Inst Owners41.07%
Inst Owner Change5.42%
Ins Owners3.93%
Ins Owner Change19.51%
Market Cap75.13M
Revenue(TTM)N/A
Net Income(TTM)-49.23M
Analysts77.14
Price Target16.32 (142.86%)
Short Float %4.46%
Short Ratio7.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-33.76%
Min EPS beat(2)-125.09%
Max EPS beat(2)57.57%
EPS beat(4)3
Avg EPS beat(4)-12.85%
Min EPS beat(4)-125.09%
Max EPS beat(4)57.57%
EPS beat(8)6
Avg EPS beat(8)0.36%
EPS beat(12)10
Avg EPS beat(12)4.45%
EPS beat(16)12
Avg EPS beat(16)9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-94.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.25%
EPS NY rev (1m)0%
EPS NY rev (3m)2.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-8.07
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-4.19
FCFYN/A
OCF(TTM)-4.19
OCFYN/A
SpS0
BVpS12.51
TBVpS12.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.6%
ROE -35.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.24
Quick Ratio 13.24
Altman-Z 0.1
F-Score3
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.48%
EPS Next Y53.37%
EPS Next 2Y31.66%
EPS Next 3Y20.77%
EPS Next 5Y11.28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.97%
OCF growth 3YN/A
OCF growth 5YN/A

IMAGENEBIO INC / IMA FAQ

Can you provide the ChartMill fundamental rating for IMAGENEBIO INC?

ChartMill assigns a fundamental rating of 3 / 10 to IMA.


Can you provide the valuation status for IMAGENEBIO INC?

ChartMill assigns a valuation rating of 1 / 10 to IMAGENEBIO INC (IMA). This can be considered as Overvalued.


How profitable is IMAGENEBIO INC (IMA) stock?

IMAGENEBIO INC (IMA) has a profitability rating of 1 / 10.


How financially healthy is IMAGENEBIO INC?

The financial health rating of IMAGENEBIO INC (IMA) is 8 / 10.